


Searching News Database: City of Hope
HSMN NewsFeed - 8 Mar 2018
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
HSMN NewsFeed - 24 Apr 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
HSMN NewsFeed - 28 Jan 2013
New NCCN Guidelines for Patients(R) Available for Adolescents and Young Adults with Cancer
New NCCN Guidelines for Patients(R) Available for Adolescents and Young Adults with Cancer
HSMN NewsFeed - 22 Jan 2013
NCCN Guidelines(R) Recommend NovoTTF(TM) Therapy as a Standard Treatment Option for CNS Cancers
NCCN Guidelines(R) Recommend NovoTTF(TM) Therapy as a Standard Treatment Option for CNS Cancers
HSMN NewsFeed - 2 Aug 2011
New NCCN Patient Guidelines Help Patients Navigate the Maze of Breast Cancer Treatment Options
New NCCN Patient Guidelines Help Patients Navigate the Maze of Breast Cancer Treatment Options
HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
HSMN NewsFeed - 5 Jan 2011
Melanoma, Ovarian, and Prostate Cancer Treatment Guidelines for Patients Available from NCCN
Melanoma, Ovarian, and Prostate Cancer Treatment Guidelines for Patients Available from NCCN
HSMN NewsFeed - 9 Dec 2010
New Multiple Myeloma Treatment Guidelines for Patients Available from NCCN
New Multiple Myeloma Treatment Guidelines for Patients Available from NCCN
HSMN NewsFeed - 26 Jan 2010
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
HSMN NewsFeed - 24 Nov 2008
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
HSMN NewsFeed - 27 Mar 2008
Oncology Researcher Forecasts Increased Use of Predictive Medicine at NCCN Conference
Oncology Researcher Forecasts Increased Use of Predictive Medicine at NCCN Conference
HSMN NewsFeed - 14 Mar 2008
Genentech Provides Business Update at Annual Investment Community Meeting
Genentech Provides Business Update at Annual Investment Community Meeting
HSMN NewsFeed - 13 Mar 2008
Sequence of Treatments May Induce Clinical Response in Metastatic Renal Cell Carcinoma Patients
Sequence of Treatments May Induce Clinical Response in Metastatic Renal Cell Carcinoma Patients
HSMN NewsFeed - 25 Feb 2008
Genentech Receives Notification of Rejection of Cabilly Patent Claims From Reexamination Process
Genentech Receives Notification of Rejection of Cabilly Patent Claims From Reexamination Process
HSMN NewsFeed - 15 May 2007
Cougar Biotechnology Announces Additions to Clinical Research and Development Team
Cougar Biotechnology Announces Additions to Clinical Research and Development Team
HSMN NewsFeed - 30 Apr 2007
NCCN Updates Prevention and Treatment of Cancer-Related Infections Guidelines
NCCN Updates Prevention and Treatment of Cancer-Related Infections Guidelines
HSMN NewsFeed - 16 Mar 2007
Robot Spurs Men's Recovery After Surgery, Urologist Says at NCCN Annual Conference
Robot Spurs Men's Recovery After Surgery, Urologist Says at NCCN Annual Conference
HSMN NewsFeed - 26 Oct 2006
Arrowhead Subsidiary, Insert Therapeutics, Inc., Raises $10 Million in Private Equity Financing
Arrowhead Subsidiary, Insert Therapeutics, Inc., Raises $10 Million in Private Equity Financing
HSMN NewsFeed - 16 May 2006
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Additional items found! 37
Members Archive contains
37 additional stories matching:
City of Hope
(Password required)
City of Hope
(Password required)
